(Source: MARKETWIRE)
Vicor Technologies, Inc. (OTCBB: VCRT) today announced that David H. Fater, President and CEO, participated in a comprehensive, in-depth interview with online publication CEOCFO. Vicor Technologies is a development-stage biotechnology company focused on the commercialization of non-invasive diagnostic products using its patented, proprietary PD2i algorithm and software to analyze heart rate variability and identify individuals at risk of sudden cardiac death, trauma victims requiring immediate life saving intervention, and diabetics at risk of developing diabetic autonomic neuropathy.
In the interview, Mr. Fater discussed recent activities involving Vicor's three diagnostic products. The Company received FDA 510(k) marketing approval late last year for its PD2i Analyzer. Under an OEM agreement with a leading manufacturer of medical diagnostic products linked to PCs, Vicor has developed the Vicor PD2i Cardiac Analyzer EKG, a state-of-the-art diagnostic tool to measure heart rate variability. According to the terms of the agreement, Vicor will co-market the new PD2i Cardiac Analyzer ECG and receive revenue from both the sale of the equipment and from analysis of the test results. The PD2i Analyzer is also currently in clinical trials to establish it as a diagnostic tool for diabetic autonomic neuropathy. The American Diabetes Association recommends that diabetics -- approximately 18 million in the U.S. alone -- receive annual screenings for this "silent killer" disease.
Under a collaborative research and development agreement (CRADA) with the U.S. Army Institute for Surgical Research, Vicor is developing the PD2i VS (Vital Sign) for use in triaging combat and civilian trauma victims. Mr. Fater anticipates FDA approval for a modification to Vicor's existing 510(k) for application in the trauma and emergency response arenas later this year, with revenue generation expected shortly thereafter.
Vicor's PD2i CA (Cardiac Analyzer), which is currently involved in multiple clinical trials, accurately identifies individuals at high risk of suffering sudden cardiac death (SCD) within a six-month time frame and could benefit from an implantable cardioverter defibrillator (ICD). Mr. Fater anticipates FDA approval for an application to risk stratify SCD during the second half of 2009.
"This is a very exciting time for Vicor," stated Mr. Fater. "Given the relatively short regulatory process of modifying our existing 510(k) and the ease of use of our product platform, we expect revenue generation to commence during the second half of this year. We believe Vicor is extremely well-positioned to grow revenues and profits quickly, as each of our products addresses a vital need of sizable at-risk populations.
